2024
Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting
Stackland S, Schnabel D, Dinan M, Presley C, Gross C. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. Journal Of The National Cancer Institute 2024, djae196. PMID: 39288939, DOI: 10.1093/jnci/djae196.Peer-Reviewed Original ResearchComprehensive genomic profilingComprehensive genomic profiling testCenter for Medical Technology PolicyClinical careClinical outcomesDiagnostic testsAssessed clinical outcomesOutcomes of patientsStrength of evidenceCourse of clinical careEfficacy of diagnostic testsNovel diagnostic testsPeer-reviewed literatureGenomic profiling testsFoundationOne CDxGenomic testingSolid tumorsStudy designGenomic alterationsGenomic profilingF1CDxCancer settingClinical utilityCancer typesCompare groups
2021
Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.
Takvorian S, Parikh R, Vader D, Wileyto E, Clark A, Lee D, Goyal G, Rocque G, Dotan E, Geynisman D, Phull P, Spiess P, Kim R, Davidoff A, Gross C, Miksad R, Calip G, Shulman L, Mamtani R, Hubbard R. Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. Journal Of Clinical Oncology 2021, 39: 1528-1528. DOI: 10.1200/jco.2021.39.15_suppl.1528.Peer-Reviewed Original ResearchAdvanced solid cancersTreatment initiationAdvanced cancer diagnosisAdvanced cancerSolid cancersCancer typesCox proportional hazards modelCOVID-19 pandemicSystemic therapy initiationSystemic treatment initiationTimely care deliveryDe novo cancerDe novo diseaseAdvanced breast cancerCancer diagnosisLife-prolonging therapiesProportional hazards modelInterrupted time series analysisDe-identified databaseProbability of treatmentNovo diseaseTherapy initiationNovo cancerPerformance statusClinical outcomes
2020
The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodes
2019
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.
Adamson B, Cohen A, Estevez M, Magee K, Williams E, Gross C, Meropol N, Davidoff A. Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. Journal Of Clinical Oncology 2019, 37: lba1-lba1. DOI: 10.1200/jco.2019.37.18_suppl.lba1.Peer-Reviewed Original ResearchTimely treatmentMedicaid expansionRacial disparitiesFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCancer ptsDiagnosis dateTreatment startAdvanced cancerMetastatic diagnosisCancer outcomesMetastatic cancerState of residenceHealthcare accessAge 18Private insuranceCancer typesExpansion statusTreatment overallCancer treatmentPractice typeTreatmentAfrican AmericansOutcomesCancer
2018
Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence
Zhou Y, Abel G, Hamilton W, Pritchard-Jones K, Gross C, Walter F, Renzi C, Johnson S, McPhail S, Elliss-Brookes L, Lyratzopoulos G. Defining, Measuring and Preventing the Diagnosis of Cancer as an Emergency: A Critical Review of Current Evidence. Journal Of Global Oncology 2018, 4: 48s-48s. DOI: 10.1200/jgo.18.45300.Peer-Reviewed Original ResearchEmergency presentationDiagnosis of cancerProportion of patientsPatient-reported outcomesPopulation-based studyHealth care useHealth care factorsHealth care interventionsPatient characteristicsPatient's symptomsLung cancerCurrent evidencePatientsDifferent tumorsCancerCancer typesLimited evidenceDiagnosisCancer diagnosisPublic healthPresentationSymptomsSuch presentationsConsistent inequalitiesRelevant evidence
2012
An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care.
Lloyd S, Buscariollo D, Gross C, Makarov D, Yu J. An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care. Journal Of Clinical Oncology 2012, 30: 6019-6019. DOI: 10.1200/jco.2012.30.15_suppl.6019.Peer-Reviewed Original ResearchRCT enrollmentMeasures of burdenCancer research effortsNCCN guidelinesNCCN recommendationsEndometrial cancerNational Comprehensive Cancer Network guidelinesEvidence-based practice guidelinesPhase 3 RCTsClinical trial enrollmentPrevalent solid tumorsTrial enrollmentNetwork guidelinesCancer careCNS cancerTreatment recommendationsClinical trialsProstate cancerPractice guidelinesSolid tumorsLife yearsMultivariate analysisMost recommendationsCancer typesCancer